Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open Label, Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study

Trial Profile

A Phase II, Open Label, Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Domatinostat (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms MERKLIN 1
  • Sponsors 4SC

Most Recent Events

  • 10 Mar 2022 This trial has been discontinued in Italy (End Date: 26 Oct 2021), according to European Clinical Trials Database record.
  • 21 Nov 2021 This trial has been discontinued in Poland (End Date: 26 Oct 2021), according to European Clinical Trials Database record.
  • 10 Nov 2021 Planned End Date changed from 1 Sep 2026 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top